Aldeyra Therapeutics
Burlington
About Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Total funding: $287.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2021)
- Ticker: nasdaq:ALDX
- Website: aldeyra.com
- Phone: +1 781 761 4904
Industries & Categories
Biotechnology, Developer Platform, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/aldeyra-therapeutics-33676 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.